Back to Search
Start Over
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
- Source :
- Saglio , G , Kim , D-W , Issaragrisil , S , le Coutre , P , Etienne , G , Lobo , C , Pasquini , R , Clark , R E , Hochhaus , A , Hughes , T P , Gallagher , N , Hoenekopp , A , Dong , M , Haque , A , Larson , R A , Kantarjian , H M , ENESTnd Investigators & Bjerrum , O W 2010 , ' Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia ' , New England Journal of Medicine , vol. 362 , no. 24 , pp. 2251-9 .
- Publication Year :
- 2010
-
Abstract
- Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.
Details
- Database :
- OAIster
- Journal :
- Saglio , G , Kim , D-W , Issaragrisil , S , le Coutre , P , Etienne , G , Lobo , C , Pasquini , R , Clark , R E , Hochhaus , A , Hughes , T P , Gallagher , N , Hoenekopp , A , Dong , M , Haque , A , Larson , R A , Kantarjian , H M , ENESTnd Investigators & Bjerrum , O W 2010 , ' Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia ' , New England Journal of Medicine , vol. 362 , no. 24 , pp. 2251-9 .
- Notes :
- English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1322183930
- Document Type :
- Electronic Resource